Business Description
Elicera Therapeutics AB
ISIN : SE0015382080
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.76 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -75.8 | |||||
3-Year EPS without NRI Growth Rate | -76.1 | |||||
3-Year FCF Growth Rate | -144 | |||||
3-Year Book Growth Rate | 1.4 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 89.15 | |||||
9-Day RSI | 79.58 | |||||
14-Day RSI | 69.51 | |||||
6-1 Month Momentum % | -80.76 | |||||
12-1 Month Momentum % | -70.61 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.23 | |||||
Quick Ratio | 4.23 | |||||
Cash Ratio | 4.16 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.2 | |||||
Shareholder Yield % | -60.35 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -80.65 | |||||
ROA % | -52.82 | |||||
ROIC % | -201.73 | |||||
ROCE % | -77.02 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.31 | |||||
Price-to-Tangible-Book | 1.42 | |||||
EV-to-EBIT | -0.18 | |||||
EV-to-Forward-EBIT | -0.09 | |||||
EV-to-EBITDA | -0.18 | |||||
EV-to-Forward-EBITDA | -0.09 | |||||
EV-to-Forward-Revenue | 4.69 | |||||
EV-to-FCF | 0.3 | |||||
Price-to-Net-Current-Asset-Value | 1.42 | |||||
Price-to-Net-Cash | 1.45 | |||||
Earnings Yield (Greenblatt) % | -460.3 | |||||
FCF Yield % | -49.32 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Elicera Therapeutics AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | |||
EPS (TTM) (kr) | -0.98 | ||
Beta | 0 | ||
Volatility % | 142.87 | ||
14-Day RSI | 69.51 | ||
14-Day ATR (kr) | 0.102117 | ||
20-Day SMA (kr) | 0.9938 | ||
12-1 Month Momentum % | -70.61 | ||
52-Week Range (kr) | 0.852 - 7.24 | ||
Shares Outstanding (Mil) | 35.09 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Elicera Therapeutics AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Elicera Therapeutics AB Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Elicera Therapeutics AB Frequently Asked Questions
What is Elicera Therapeutics AB(OSTO:ELIC)'s stock price today?
When is next earnings date of Elicera Therapeutics AB(OSTO:ELIC)?
Does Elicera Therapeutics AB(OSTO:ELIC) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |